Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer

Ivosidenib is an isocitrate dehydrogenase mutant inhibitor that the US Food and Drug Administration recently approved for the treatment of leukemia. Studies suggested that ivosidenib may inhibit the progression of non-small cell lung cancer (NSCLC). In the present study, we explored RNAs and their p...

Full description

Bibliographic Details
Main Authors: Juan Wu, Ru Chen, Huiqing Shen, Ting Yan, Yu Qian, Yaping Zhang, Zhuoya Huang, Pengzhou Kong, Min Pang, Xinri Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.626605/full